AI Article Synopsis
- Edoxaban, a direct factor Xa inhibitor, doesn't need regular monitoring but may require assessments of its anticoagulant effects in specific cases.
- The study examined how edoxaban impacts prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation using different types of plasma.
- Results showed that while PT and aPTT were prolonged with increased edoxaban levels, PT had more variability between reagents, making aPTT a more consistent test, whereas thrombin generation was the most sensitive to edoxaban effects.*
Article Abstract
Objectives: Edoxaban, an oral direct factor Xa inhibitor, does not require routine monitoring. However, assessment of the anticoagulant effects may be required in certain situations.
Methods: We investigated the effects of edoxaban on prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin generation using human platelet-poor plasma (PPP) or platelet-rich plasma (PRP).
Results: Edoxaban concentration-dependently prolonged PT and aPTT. There was a considerable variation in the magnitude of PT prolongation among the reagents used. The variability in aPTT prolongation among the reagents was smaller than that of PT. Edoxaban concentration-dependently inhibited thrombin generation, with a more potent effect seen in PPP than in PRP. Thrombin generation assay was three times more sensitive to edoxaban than PT and aPTT.
Conclusions: PT had disadvantages of a large variability among different PT reagents. aPTT could be used as a conventional and convenient test with a smaller variation among reagents. Thrombin generation was the most sensitive assay.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1309/AJCPQ2NJD3PXFTUG | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bleeding Symptoms in Pediatric Patients with Congenital FVII Deficiency and Correlation to Thrombin Generation Assay Parameters: A Single-Center Retrospective Analysis.
Life (Basel)
November 2024
Onco-Hematology, Cell and Gene Therapy and Bone Marrow Transplant Clinic Area, Bambino Gesù Children's Hospital, IRCCS, 00165 Rome, Italy.
Inherited factor VII deficiency is the most common rare bleeding disorder, affecting about 1/500,000 individuals without gender predilection. Most of the patients with FVII 20-50% are asymptomatic, but post-traumatic or post-surgical bleeding may often occur since there is not an exact correlation between FVII plasma levels and the bleeding phenotype. We enrolled 19 children and adolescents with FVII levels of 20-35% and 33 controls.
View Article and Find Full Text PDFTRAP-Induced Platelet Reactivity Is Inhibited by Omega-3 Fatty Acid-Derived Prostaglandin E3 (PGE3).
Biomedicines
December 2024
Department of Physiology, University of Murcia, 30120 Murcia, Spain.
Prostaglandins are naturally occurring local mediators that can participate in the modulation of the cardiovascular system through their interaction with Gs/Gi-coupled receptors in different tissues and cells, including platelets. Thrombin is one of the most important factors that regulates platelet reactivity and coagulation. Clinical trials have consistently shown that omega-3 fatty acid supplementation lowers the risk for cardiovascular mortality and morbidity.
View Article and Find Full Text PDF[Pedigree analysis of novel missense mutations causing hereditary coagulation factor Ⅴ deficiency].
Zhonghua Xue Ye Xue Za Zhi
December 2024
Department of Clinical Laboratory, Key Laboratory of Clinical Laboratory Diagnosis and Translational Research of Zhejiang Province, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325015, China.
This study aimed to primarily discuss the pathogenesis of hereditary coagulation factor Ⅴ (FⅤ) deficiency in a family with a consanguineous cousin marriage. The coagulation indices of the pedigree (three generations with seven individuals) and the thrombin levels of the proband and his father were assessed. All exons of the F5 gene were analyzed with Sanger sequencing, and a new mutation was confirmed with reverse sequencing.
View Article and Find Full Text PDFBrolucizumab and Platelet Activation and Reactivity.
Curr Eye Res
January 2025
Centre for Ophthalmology, Eberhard-Karls University, Tübingen, Germany.
Purpose: This study explores the potential interaction of brolucizumab with platelets and its effects on platelet activation and reactivity, crucial in retinal vasculitis and retinal vascular occlusion. Safety concerns remain of interest, although brolucizumab showed superior retinal efficacy and reduced injection frequency compared to other licensed anti-VEGF agents.
Methods: Resting and activated platelets of healthy volunteers were pretreated with brolucizumab at the following concentrations 0.
How Dendrimers Impact Fibrin Clot Formation, Structure, and Properties.
ACS Omega
December 2024
Department of Biochemistry, Federal University of São Paulo, São Paulo, SP 04044-020, Brazil.
Article Synopsis
- PAMAM dendrimers, known for their structural versatility and customizable surfaces, are being investigated for biomedical uses, but their interactions with blood can disrupt normal clotting and pose health risks.
- The study focused on how low-generation PAMAM dendrimers affect fibrin clot formation dynamics, including clot structure and resistance to breakdown, using various methods and blood samples.
- Notably, certain dendrimers like G2-NH and G4-NH hindered clot formation and altered clot properties significantly, while G3.5-COOH showed minimal impact, suggesting it could be a safer option for medical applications.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!